TipRanks
Editas Medicine Inc (EDIT)
NASDAQ:EDIT
US Market
EDIT
Editas Medicine
RESEARCH TOOLSreports
Want to see EDIT full AI Analyst Report?

Editas Medicine (EDIT) Stock News & Sentiment

3,586 Followers
Phil Nadeau Reiterates Buy on Editas Medicine, Citing Strong Cash Runway and Upcoming EDIT-401 Clinical Catalyst
Premium
Ratings
Phil Nadeau Reiterates Buy on Editas Medicine, Citing Strong Cash Runway and Upcoming EDIT-401 Clinical Catalyst
1M ago
EDIT
Editas Medicine Strengthens Board With New Cardiology Director
Premium
Company Announcements
Editas Medicine Strengthens Board With New Cardiology Director
1M ago
8K
EDIT
EDIT Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
EDIT Earnings this Week: How Will it Perform?
2M ago
EDIT
Editas Medicine Shareholders Back Board, Pay and Auditor
Premium
Company Announcements
Editas Medicine Shareholders Back Board, Pay and Auditor
3M ago
8K
EDIT
Editas Medicine Raises Capital Through Public Equity Offering
Premium
Company Announcements
Editas Medicine Raises Capital Through Public Equity Offering
4M ago
8K
EDIT
Editas Medicine Suspends Existing At-The-Market Offering Prospectus
Premium
Company Announcements
Editas Medicine Suspends Existing At-The-Market Offering Prospectus
4M ago
8K
EDIT
Editas Showcases Promising EDIT-401 Data for Hyperlipidemia
Premium
Company Announcements
Editas Showcases Promising EDIT-401 Data for Hyperlipidemia
4M ago
8K
EDIT
More EDIT News >

EDIT News on the Web

Editas Medicine files $400M mixed securities shelf
TipRanks News
Bullish
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT)
TipRanks News
Bullish
Editas Medicine Inc Annual Shareholders Meeting Transcript
GuruFocus News
Neutral
Private Markets: Bezos’ Prometheus raises $12B as OpenAI files for IPO
TipRanks News
Neutral
RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc
GuruFocus News
Neutral
COMMODORE CAPITAL LP Acquires Significant Stake in Editas Medicine Inc
GuruFocus News
Neutral
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
The Motley Fool
Bearish
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026? | The Motley Fool
Motley Fool
Bearish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average1.25 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is EDIT’s Media Buzz Sentiment?
Currently, no data Available
What is EDIT’s weekly average amount of articles?
In an average week, 1.25 articles about EDIT are published.
    What is EDIT’s News Sentiment?
    Currently, no data Available
    Healthcare Stocks that are Trending in the News
    VCYTVeracyte
    BMYBristol-Myers Squibb
    SLDBSolid Biosciences
    DFTXDefinium Therapeutics
    LHLabcorp Holdings
    Showing the stocks with the most bullish news sentiment over the past week